Juvaris BioTherapeutics News
Most Popular Juvaris BioTherapeutics Story
Juvaris completes $25M close of series B
Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. The Burlingame, CA-based company says it will use the capital to advance its technology platform... Read more...
Latest Headlines
- September 17, 2009
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
